Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.62 |
| ▸ | PDE1A | P54750 | 6/20 | 0.62 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.62 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.62 |
| ▸ | PDE4A | P27815 | 3/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.62 |
| ▸ | CFTR | P13569 | 2/20 | 0.62 |
| ▸ | PDE5A | O76074 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | SCN1A | P35498 | 1/20 | 0.62 |
| ▸ | PDE6C | P51160 | 1/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.62 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theophylline Anhydrous SCHEMBL8312163 | 0.77 | ATAD2 (0.53) | PDE2APDE1APDE1BPDE1CPDE4A | |
| Isobutylmethylxanthine SCHEMBL50315 | 0.77 | PDE4A (1.00) | PDE2APDE1APDE1BPDE1CPDE4A | |
| Isobutylmethylxanthine SCHEMBL28814716 | 0.77 | PDE4A (1.00) | PDE2APDE1APDE1BPDE1CPDE4A | |
| Isobutylmethylxanthine SCHEMBL7637581 | 0.74 | PDE4A (0.94) | PDE2APDE1APDE1BPDE1CPDE4A | |
| SCHEMBL1713619 | 0.74 | ADORA2A (0.45) | PDE2APDE1APDE1BPDE1CPDE4A | |
| SCHEMBL239725 | 0.73 | CFTR (1.00) | PDE2APDE1APDE1BPDE1CPDE4A | |
| Isobutylmethylxanthine SCHEMBL4262798 | 0.73 | PDE4A (0.92) | PDE2APDE1APDE1BPDE1CPDE4A | |
| SCHEMBL29015261 | 0.72 | ADORA2A (0.46) | PDE2APDE1APDE1BPDE1CPDE4A | |
| SCHEMBL28814714 | 0.72 | PDE1A (0.49) | PDE2APDE1APDE1BPDE1CPDE4A | |
| SCHEMBL13111707 | 0.72 | PDE1A (0.49) | PDE2APDE1APDE1BPDE1CPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988746-A | A kind of mescenchymal stem cell adipogenic induction differentiation method | 上海葆年生物科技有限公司 | 2019-07-09 | — | — | CN | claimed |
| US-20190083455-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-21 | — | — | US | claimed |
| CN-107858327-A | Separation, culture and the method for inducing differentiation of the intramuscular Preadipocyte In Vitro of one breeder | 河南农业大学 | 2018-03-30 | — | — | CN | claimed |
| CN-107858326-A | Murine preadipocyte cell 3T3 L1 differentiation-inducing agents and method of inducing differentiation | 上海银海圣生物科技有限公司 | 2018-03-30 | — | — | CN | claimed |
| CN-107184623-A | A kind of preparation method and applications of ardisia japonica alcohol extract | 天津中医药大学 | 2017-09-22 | — | — | CN | claimed |
| US-20170105964-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | claimed |
| WO-2015195894-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS | THE GENERAL HOSPITAL CORPORATION (US) | 2015-12-23 | — | — | WO | claimed |
| EP-1583541-A2 | COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS | Neuronova AB (SE) | 2005-10-12 | — | — | EP | claimed |
| US-20050009847-A1 | Compounds and methods for increasing neurogenesis | NEURONOVA AB (COMPANY REGISTRATION NO. 556703-0118) (SE) | 2005-01-13 | — | — | US | claimed |
| WO-2004045592-A2 | COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS | NEURONOVA AB (SE) | 2004-06-03 | — | — | WO | claimed |
| US-20250295714-A1 | LACTOBACILLUS PARACASEI STRAIN OR LACTOBACILLUS PLANTARUM STRAIN DERIVED FROM HUMAN BODY, HAVING BODY FAT REDUCING ACTIVITY, AND MIXTURE COMPOSITION COMPRISING SAME | HECTO HEALTHCARE CO., LTD. (KR) | 2025-09-25 | — | — | US | disclosed |
| CN-117982734-A | Breast patch and preparation method thereof | 中国人民解放军总医院第一医学中心 | 2024-05-07 | — | — | CN | disclosed |
| CN-117805360-A | Functional nucleic acid aptamer screening method combining cell screening and functional screening targeting GPCR (GPCR) protein and application | 温州医科大学附属眼视光医院 | 2024-04-02 | — | — | CN | disclosed |
| CN-117750950-A | Composition containing benzyl ethanolamine derivative as active ingredient for preventing or treating metabolic diseases | JL生物疗法公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024029670-A1 | LACTOBACILLUS HELVETICUS BCC-LH-04 HAVING BODY FAT REDUCTION ACTIVITY, AND COMPOSITIONS COMPRISING SAME | (주)헥토헬스케어 | 2024-02-08 | — | — | WO | disclosed |
| WO-2004045592-A2 | COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS | NEURONOVA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
| EP-0755255-A4 | TREATMENT OF TOXOPLASMOSIS | RES CORP TECHNOLOGIES INC (US) | 2002-07-24 | — | — | EP | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295714-A1 | LACTOBACILLUS PARACASEI STRAIN OR LACTOBACILLUS PLANTARUM STRAIN DERIVED FROM HUMAN BODY, HAVING BODY FAT REDUCING ACTIVITY, AND MIXTURE COMPOSITION COMPRISING SAME | LPL, LIPC, LCT | PDE2A 2016/4885PDE1A 4555/4885PDE1B 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.